Ritlecitinib
Last Updated: 04/28/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 202 publications
Post-marketing safety signals of four JAK inhibitors for alopecia areata: an indication-restricted FAERS pharmacovigilance study.
Journal: The Journal of dermatological treatment
Published: April 01, 2026
Dynamics of Lipid Profile in Patients With Alopecia Areata Treated With Ritlecitinib: A Descriptive, Retrospective, Real-World Study.
Journal: Journal of cutaneous medicine and surgery
Published: March 27, 2026
Use of oral Janus kinase inhibitors for the treatment of severe alopecia areata: narrative review and real-world experience.
Journal: Immunological medicine
Published: March 27, 2026
Real-World Efficacy of Ritlecitinib in Adolescent Patients With Alopecia Areata: A 36 Week Monocentric Real-Life Observational Study.
Journal: Journal of cutaneous medicine and surgery
Published: March 12, 2026
Regrowth of Eyebrows in a Previous Steroid Non-Responder With Alopecia Universalis After Ritlecitinib Treatment.
Journal: Journal of drugs in dermatology : JDD
Published: March 04, 2026
Exploring novel management options for alopecia areata.
Journal: The American journal of managed care
Published: March 04, 2026
Efficacy, Safety, and Real-World Aspects of Janus Kinase Inhibitors to Treat Patients With Alopecia Areata.
Journal: Journal of drugs in dermatology : JDD
Published: March 04, 2026
Long-Term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-Year Results from the ALLEGRO Phase 2b/3 and ALLEGRO-LT Phase 3 Clinical Studies.
Journal: American journal of clinical dermatology
Published: February 20, 2026
Advances in Janus Kinase Inhibitors for Vitiligo Treatment.
Journal: Drug research
Published: February 05, 2026
Alopecia Areata and Atopic Dermatitis: Common Mechanisms and Emerging Therapeutics.
Journal: Journal of inflammation research
Published: January 22, 2026
Last Updated: 04/28/2026